Identification of TP53 mutations in circulating tumour DNA in high grade serous ovarian carcinoma using next generation sequencing technologies

Plasma circulating tumour DNA (ctDNA) has been suggested to be a viable biomarker of response to treatment in patients with high grade serous ovarian carcinoma (HGSOC). TP53 mutations are present in more than 90% of HGSOCs but somatic variants are distributed across all exonic regions of the gene, r...

Descripción completa

Detalles Bibliográficos
Autores principales: Calapre, Leslie, Giardina, Tindaro, Beasley, Aaron B., Reid, Anna L., Stewart, Colin, Amanuel, Benhur, Meniawy, Tarek M., Gray, Elin S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9822997/
https://www.ncbi.nlm.nih.gov/pubmed/36609632
http://dx.doi.org/10.1038/s41598-023-27445-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9822997/
https://www.ncbi.nlm.nih.gov/pubmed/36609632
http://dx.doi.org/10.1038/s41598-023-27445-2

Ejemplares similares